Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: A double-blind, double-dummy, randomized multicenter study

Inflammatory Bowel Diseases

Volumn 19, Issue 8, 2013, Pages 1681-1690

  Watanabe, Mamoru ^a   Hanai, Hiroyuki ^b   Nishino, Haruo ^c   Yokoyama, Tadashi ^d   Terada, Toshiaki ^e   Suzuki, Yasuo ^f  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Hamamatsu South Hospital   (Japan)

^c Matsushima Clinic ^*  (Japan)

^d Yokoyama Hospital for Gastroenterological Diseases   (Japan)

^e Department of Orthopedic Surgery   (Japan)

^f TOHO UNIVERSITY   (Japan)

Author keywords

Double blind; Double dummy; Maintenance; Mesalazine; Ulcerative colitis

Indexed keywords

MESALAZINE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION;

EID: 84884551836     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318286fa3d     Document Type: Article

References (28)

1. st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastem Norway, 1990-93. Scand J Gastroenterol. 1997;32:1005-1012.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347: 417-429.
3. Lakatos PL, Lakatos L. Ulcerative proctitis: a review of pharmacotherapy and management. Expert Opin Pharmacother. 2008;9:741-749.
4. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology. 2004;126:1582-1592.
5. Kornbluth A, Sachar DB, The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-523.
6. Travis SPL, Stange EF, Lemann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008;2:24-62.
7. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006: CD000544.
8. Fockens P, Mulder CJ, Tytgat GN, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol. 1995;7:1025-1030.
9. Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. Ann Intern Med. 1996;124:204-211.
10. Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut. 2001;49:783-789.
11. Paoluzi OA, Lacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther. 2005;21:1111-1119.
12. Wolfgang FW, Maria A, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry. 2003;64(Suppl 16):10-13.
13. Kamishima K, Otaka T, Takahashi T, et al. Drug adherence. Psychiat Neurol Jpn. 2005;107:696-703.
14. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114: 39-43.
15. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.
16. Ford AC, Khan KJ, Sandborn WJ, et al. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2001; 296:1-8.
17. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoidis, and proctitis. Gastroenterology. 1987;92:1894-1898.
18. Schroeder KW, Tremaine WJ, Iistrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317:625-629.
19. Velayos FS, Terdiman JP, Walsh JM. Effects of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.
20. Shintoh M, Shimada Y, Konishi K, et al. Enhancement of outpatient medication teaching by pharmacists. J Jpn Soc Hosp Pharm. 1999;35: 23-26.
21. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once-or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57:893-902.
22. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:762-769.
23. Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayedrelease oral mesalamine (400-mg tablet) is as effective as twice-daily for maintenance of remission of ulcerative colitis. Gastroenterology. 2010; 138:1286-1296.
24. Kruis W, Jonatis L, Pokrotnieks J, et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011;33:313-322.
25. Nugent SG, Kumar D, Rampton DS, et al. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001; 48:571-577.
26. Higaki H, Nakayama S, Tanaka Y, et al. Phase 1 study; the prolongedrelease oral mesalazine preparations-single and multiple studies. Jpn Pharmacol Ther. 1994;22:5-45.
27. Mitsuyama K, Harada K, Yamasaki H, et al. 5-Aminosalicylic acid released from mesalazine tablet-comparison of pharmacokinetic parameters between Japanese patients with ulcerative colitis and healthy adults. Asian J Chem. 2012;24:3357-3361.
28. Kane S, Hou D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003;1:170-173.